ArticleNature2025
Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers.
0numbers the graph read from it
0cells of the map it votes in
110citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed.
- Efficacy, immunogenicity, and safety of heterologous boosting with a novel chimera Chinese mRNA (RQ3013) SARS-CoV-2 vaccine: A randomized, double-blind, active-controlled trial.Human vaccines & immunotherapeutics · 2025Trial
- Age-associated differences in XBB.1.5 trivalent booster vaccine-induced adaptive responses revealed by single-cell RNA sequencing.Emerging microbes & infections · 2026Article
- A Dual-Membrane Biomimetic Nanoplatform Enables Triple-Modal Therapy Against SARS-CoV-2 Through Viral Decoy, Inflammation Neutralizing, and Intracellular RNAi.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A dimeric mRNA vaccine based on key-mutant and KP.3 RBDs induces broad-spectrum immunity and protects mice against JN.1 and XDV challenges.Molecular biomedicine · 2026Article
- An Engineered HR1-Stem Helix-HR2 Trimeric Platform for Developing Broad-Spectrum Coronavirus Vaccines.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Potent type-specific de novo antibodies complement broadly reactive imprinted antibodies in immune responses to SARS-CoV-2 variants.Nature immunology · 2026Article
- From sites to structure to serology: a roadmap for structure-aware molecular evolution of antigenically evolving viruses.Journal of virology · 2026Review
- Tracking the shifting landscape of SARS-CoV-2 variants in Lebanon among healthcare workers and hospitalized patients.Microbiology spectrum · 2026Article
- Durability and Breadth of Neutralizing Antibodies Against SARS-CoV-2 Variants Following XBB.1.5 Vaccination in a Multiply Exposed Cohort.Open forum infectious diseases · 2026Article
- Receptor-mimicking antibodies retain neutralization of recent SARS-CoV-2 variants.Biosafety and health · 2026Article
- JN.1-adapted vaccination is associated with readjustment of ancestral memory B cells toward neutralization within the JN.1 antigenic space.Nature communications · 2026Article
- Localized Rigidification and Allosteric Modulation Mechanisms of SARS-CoV-2 Spike Neutralization by Class 3 and Class 4 Antibodies at Atomic Resolution: An Integrated Computational Study of Binding, Dynamics, and Allostery.bioRxiv : the preprint server for biology · 2026Article
- A deep mutational scanning-informed protein language model predicts SARS-CoV-2 evolution dynamics with spatiotemporal resolution.Nature microbiology · 2026Article
- Altered infectivity, cell-cell fusion, and immune evasion of SARS-CoV-2 BA.3.2 and LP.8.1 variants.Journal of virology · 2026Article
- A decoy virus strategy using plant-produced SARS-CoV-2 virus-like-particles to inhibit infection and lung injury.Journal of translational medicine · 2026Article
- Induction of Humoral and Cellular Immunity After SARS-CoV-2 JN.1 Vaccination in Individuals With and Without Prior Infection.European journal of immunology · 2026Article
- MAAD: multidimensional antiviral antibody database.Protein & cell · 2026Article
- Predictive modeling of immune escape and antigenic grouping of SARS-CoV-2 variants.Journal of virology · 2026Article
- Epistasis and background dependence in the evolution of Omicron variants of the SARS-CoV-2 spike protein.Molecular biology and evolution · 2026Article
- Mechanisms of Binding and Immune Escape Resistance for Broadly Neutralizing Antibodies Targeting Distinct Conserved SARS-CoV-2 Spike Epitopes: A Hierarchical Approach Integrating Mutational Profiling and Energy Landscape Analysis.International journal of molecular sciences · 2026Article
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Fanchong Jian *Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, China.ORCID 0000-0001-8703-3507
Jing Wang *Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, China.ORCID 0000-0002-9084-9985
Ayijiang Yisimayi *Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, China.ORCID 0000-0003-0648-1864
Weiliang Song *Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, China.
Yanli Xu *Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Xiaosu ChenInstitute for Immunology, College of Life Sciences, Nankai University, Tianjin, China.
Xiao NiuBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, China.
Sijie YangBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, China.ORCID 0009-0001-9834-4340
Yuanling YuChangping Laboratory, Beijing, China.
Peng WangChangping Laboratory, Beijing, China.
Haiyan SunChangping Laboratory, Beijing, China.
Lingling YuChangping Laboratory, Beijing, China.
Jing WangChangping Laboratory, Beijing, China.
Yao WangChangping Laboratory, Beijing, China.
Ran AnChangping Laboratory, Beijing, China.
Wenjing WangChangping Laboratory, Beijing, China.
Miaomiao MaChangping Laboratory, Beijing, China.
Tianhe XiaoBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, China.
Qingqing GuChangping Laboratory, Beijing, China.ORCID 0000-0001-5805-6419
Fei ShaoChangping Laboratory, Beijing, China.
Youchun WangChangping Laboratory, Beijing, China.ORCID 0000-0001-9769-5141
Zhongyang ShenOrgan Transplant Center, NHC Key Laboratory for Critical Care Medicine, Tianjin First Central Hospital, Nankai University, Tianjin, China.ORCID 0000-0003-0045-4355
Ronghua JinBeijing Ditan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0001-8496-172X
Yunlong CaoBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, China. yunlongcao@pku.edu.cn.ORCID 0000-0001-5918-1078
Funding
No grant is acknowledged in the PubMed record.
Abstract
The continuous evolution of SARS-CoV-2, particularly the emergence of the BA.2.86/JN.1 lineage replacing XBB, necessitates re-evaluation of vaccine compositions
Indexed as
Antibodies, ViralAntigenic Drift and ShiftCOVID-19SARS-CoV-2Antibodies, NeutralizingB-LymphocytesCOVID-19 VaccinesFemaleHumansImmune EvasionImmunity, HumoralImmunologic MemoryMaleMemory B CellsSpike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.